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rrent fortifier.Objectives: The aim of this study was to assess growth and nutritional
biomarkers of preterm infants fed human milk (HM) supplemented with a
new powdered HM fortifier (nHMF) or a control HM fortifier (cHMF). The
nHMF provides similar energy content, 16% more protein (partially hydro-
lyzed whey), and higher micronutrient levels than the cHMF, along with
medium-chain triglycerides and docosahexaenoic acid.
Methods: In this controlled, multicenter, double-blind study, a sample of
preterm infants 32 weeks or 1500 g were randomized to receive nHMF
(n¼ 77) or cHMF (n¼ 76) for a minimum of 21 days. Weight gain was
evaluated for noninferiority (margin¼ –1 g/day) and superiority
(margin¼ 0 g/day). Nutritional status and gut inflammation were assessed
by blood, urine, and fecal biochemistries. Adverse events were monitored.
Results: Adjusted mean weight gain (analysis of covariance) was 2.3 g/day
greater in nHMF versus cHMF; the lower limitof the 95% CI (0.4 g/day) exceeded
both noninferiority (P< 0.001) and superiority margins (P¼ 0.01). Weight gain
rate (unadjusted) was 18.3 (nHMF) and 16.8 g  kg1  day1 (cHMF) between
study days 1 and 21 (D1–D21). Length and head circumference (HC) gains
between D1 and D21 were not different. Adjusted weight-for-age z score at D21
and HC-for-age z score at week 40 corrected age were greater in nHMF versus
cHMF (P¼ 0.013, P¼ 0.003 respectively). nHMF had higher serum blood urea
nitrogen, pre-albumin, alkaline phosphatase, and calcium (all within normal
ranges; all P 0.019) at D21 versus cHMF. Both HMFs were well tolerated
with similar incidence of gastrointestinal adverse events.
Conclusions: nHMF providing more protein and fat compared to a control
fortifier is safe, well-tolerated, and improves the weight gain of preterm infants.
Key Words: growth, human milk, low birth weight
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Rigo et al JPGN  Volume 65, Number 4, October 2017protective effect on neurodevelopment (5)) that are mediated by
protective biomolecules and trophic factors in HM. HM, however,
provides inadequate protein and micronutrients to support the rapid
growth and bone mineralization of preterm infants. These deficits
are particularly acute in the smallest infants (birthweight <1500 g)
who have the highest protein and mineral needs (6). Fortification of
mother’s own milk or banked HM is therefore recommended for all
preterm infants with birthweight <1800 g to improve nutrient
accretion and in-hospital growth (7,8).
Feeding fortified HM helps support adequate growth and
bone mineralization (9), and is associated with favorable neurode-
velopmental outcomes (10), although evidence for improved out-
comes other than in-hospital growth is limited (11). The nutritional
content, however, of some currently available fortifiers may be
inadequate for many preterm infants. Incidence of postnatal growth
restriction is more frequently reported in very-low-birth-weight
infants fed fortified HM compared to those fed preterm formulas
(12,13). In addition, the nutritional profile of HM from mothers of
premature infants varies greatly (14) and may differ from published
reference compositional data, which may lead to less-than-recom-
mended intakes of protein and energy (15,16). These nutritional
inadequacies may worsen with use of donor HM, which is often
from mothers of term infants >1-month postpartum (17).
A new powdered HM fortifier has been developed with a
higher protein:energy ratio (protein provided as partially hydro-
lyzed whey), non-protein energy from lipids and carbohydrate, and
higher electrolyte and vitamin levels (enriching HM in line with
ESPGHAN (18) and expert group (19) recommendations) versus a
control fortifier. When mixed with HM containing 1.5 g protein/
100 mL (2–4 week milk) (20–22), it provides 3.6 g protein/100 kcal
(within the ESPGHAN-recommended ranges (18) for protein and
energy intakes for a minimal intake volume of 140 mL/kg/day in
very-low-birth-weight infants up to 1.8 kg body weight), with
osmolality below the recommended threshold of 450 mOsm/kg
(23,24).
This study evaluated growth and nutritional biomarkers
during a 21-day interval in clinically stable preterm infants receiv-
ing the new HM fortifier (nHMF) compared to infants fed a control
fortifier (cHMF). The primary objective was to assess weight gain
velocity (grams per day); evaluations of other growth parameters
(including weight gain velocity in gram per kilograms per day) and
intervals (eg, to 40 weeks corrected age [W40CA]), feeding toler-
ance, adverse events, time to full fortification/full enteral feeding,
and markers of protein-energy, electrolytes, bone metabolic status,
gut inflammation, and maturity of gastrointestinal (GI) function
were also conducted as secondary outcomes. We hypothesized that
weight gain of infants fed nHMF would be both noninferior (lower
limit of 95% confidence interval [CI] of mean difference >–1 g/
day) and superior (lower limit of 95% CI of mean difference >0 g/
day) to that of infants fed cHMF.
METHODS
Study design and participants
This was a controlled, double-blind, randomized, parallel-
group study conducted in neonatal intensive care units (NICUs) at
11 metropolitan hospitals in France, Belgium, Germany,
Switzerland, and Italy. NICU size ranged from 25 to 45 beds.
Clinically stable male and female preterm infants with gestational
age 32 weeks or birthweight 1500 g and born to mothers who
had agreed to provide expressed or donor breastmilk for the entire
21-day study duration were enrolled in the study from April 2011 to
March 2014. Infants were excluded if they had a history of or
current systemic, metabolic, or chromosomic disease, any congeni-
tal anomalies of the GI tract, were small for gestational age (definede84in this study as bodyweight 5 percentile (25)), or were receiving
steroids or preterm formula during the study period. For multiple
births, the first sibling was randomized and other siblings were
allocated to the same group. The study was reviewed and approved
by an institutional review board/independent Ethics Committee at
each study site. Each subject’s parent/legal representative provided
written informed consent before participating in the study.
Infants tolerating 100 mL  kg1  day1 of HM for
>24 hours were randomized to receive either nHMF or cHMF for
a minimum of 21 days; infants continued to receive their allocated
study fortifier (or were transitioned to a routine/standard fortifier)
until NICU discharge or medical decision to stop fortification, and
fortification was stopped after discharge. The fortifiers were both
cow’s milk-based and provided similar energy supplementation
(17 kcal/100 mL of HM). For every 100 mL of HM, nHMF provided
1.4 g partially hydrolyzed whey protein, 0.7 g lipids (primarily medi-
um chain triglycerides and docosahexaenoic acid), 1.3 g carbohydrate
(maltodextrin), with a blend of micronutrients. cHMF (FM85 Human
Milk Fortifier, Nestle´, Switzerland) provided 1.0 g extensively hy-
drolyzed whey protein, no lipids, 3.3 g carbohydrate (lactose and
maltodextrin), with a blend of micronutrients. nHMF contained
higher concentrations of some vitamins and electrolytes compared
to cHMF, but both contained similar levels of minerals, including
calcium (as calcium glycerophosphate and calcium phosphate) and
phosphorus. Table 1 presents the estimated composition and osmo-
lality of preterm HM (22) fortified with each fortifier. Fortifiers were
fed beginning at half-strength (Fortification Strength Increase day 1;
FSI1), then advanced per hospital practice, with full-strength fortifi-
cation occurring once infants could maintain intakes of 150 to
180 mL  kg1  day1 (ie, full enteral feeds; study day 1 [D1]). A
study plan schematic is presented in Figure 1.
Study Procedures
Growth
Infant nude weight (to the nearest 1 g) was measured daily by
trained nursery personnel using a calibrated electronic scale (Baby
Scale 717, Seca, Semur-en-Auxois, France). Recumbent length and
head circumference (HC; both to the nearest 0.1 cm) were measured
at FSI1, D1, and weekly thereafter. At least 2 trained examiners
measured recumbent length using a length board (Mobile Measur-
ing Board 417, Seca, Semur-en-Auxois, France) while maintaining
proper body alignment and full body extension with feet flexed. HC
was measured using a nonelastic measuring tape (Measuring Tape
212 or 218, Seca, Semur-en-Auxois, France) placed over the largest
circumference of the skull (above the supraorbital ridges while
covering the most prominent part of the frontal bulge anteriorly).
The same calibrated equipment was used for anthropometric mea-
sures for each infant at all sites. Weight-for-age, length-for-age, and
HC-for-age z scores were calculated using Fenton (25). Weight gain
velocity (grams per kilograms per day) was calculated using the
average of the start and end weights as the denominator.
Markers of Protein-energy, Electrolyte, and Bone
Metabolic Status
Blood and urine samples were collected at D1, D10/11, and
D21 and analyzed for serum creatinine and prealbumin, blood urea
nitrogen (BUN), urinary urea, hemoglobin, hematocrit, electrolyte
status, and bone metabolic status. All blood and urine parameters
were analyzed as part of routine clinical assessments at each NICU.
Since 24-hour urine collections were not performed in this study
owing to logistical infeasibility, urinary markers were corrected for
24-hour creatinine excretion (26) assuming a standard urinary
excretion in preterm infants of 10 mg  kg1  day1 (27).www.jpgn.org
TABLE 1. Calculated

nutrient composition of fortified preterm human milk
Preterm HMþ nHMF Preterm HMþ cHMF
4 g fortifier
alone
4 g fortifier
per 100 kcal
milk
4 g fortifier
per 100 mL
milk
5 g fortifier
alone
5 g fortifier
per 100
kcal milk
5 g fortifier
per 100
mL milk
Recommended
intake range
(per 100 kcal)y
Nutrient
Energy, kcal 17.4 100 84.6 17.4 100 84.5
Protein, g 1.42 3.6 3.04 1.0 3.10 2.62 3.2–4.1
Protein source Partially hydrolyzed whey Extensively hydrolyzed whey
Fat, g 0.72 5.00 4.23 0.02 4.16 3.52 4.4–6
MCT, g 0.50 0.59 0.50 0 0 0
DHA, mg 6.3 19.3 16.3 0 11.8 10.0 (16.4–) 50–55
Carbohydrate, g 1.30 10.17 8.60 3.30 12.53 10.60 10.5–12
Carbohydrate source Maltodextrin Lactose and maltodextrin
Calcium, mg 76 119 101 75 118 100 109–182
Phosphorus, mg 44 69 58 45 70 59 55–127
Magnesium, mg 4.0 8.6 7.3 2.4 6.7 5.7 7.3–13.6
Sodium, mg 36.7 76.5 64.7 20.0 56.8 48.0 63–105
Potassium, mg 48.4 116.4 98.4 42.0 108.8 92.0 71–177
Chloride, mg 32.1 106.6 90.1 17.0 88.7 75.0 95–161
Iron, mg 1.80 2.23 1.89 1.30 1.64 1.39 1.8–2.7
Zinc, mg 0.94 1.55 1.31 0.80 1.38 1.17 1.3–2.3
Manganese, mg 8.08 9.98 8.44 5.00 6.34 5.36 0.9–13.6
Copper, mg 0.05 0.11 0.09 0.04 0.09 0.08 0.09–0.21
Iodine, mg 16.9 36.6 30.9 15.0 34.3 29.0 9–50
Selenium, mg 3.7 7.2 6.1 1.5 4.6 3.9 4.5–9
Vitamin A, IU 1183 1754 1483 500 946 800 1217–3333
Vitamin D, IU 150 187 158 100 128 108 100–350
Vitamin E, IU 4.4 5.6 4.7 2.2 3.0 2.5 2.2–11.1
Vitamin K, mg 8.0 9.8 8.3 4.0 5.1 4.3 4–25
Thiamin, mg 0.15 0.19 0.16 0.05 0.07 0.06 0.13–0.27
Riboflavin, mg 0.20 0.27 0.23 0.10 0.15 0.13 0.18–0.36
Vitamin B6, mg 0.13 0.16 0.14 0.05 0.07 0.06 0.05–0.27
Vitamin B12, mg 0.20 0.26 0.22 0.10 0.14 0.12 0.09–0.73
Niacin, mg 1.50 2.02 1.71 0.80 1.19 1.01 0.9–5
Folic acid, mg 40.0 51.0 43.1 40.0 51.0 43.1 32–91
Pantothenic acid, mg 0.70 1.10 0.93 0.40 0.74 0.63 0.45–1.9
Biotin, mg 3.50 4.78 4.04 3.00 4.19 3.54 1.5–15
Vitamin C, mg 20.0 28.9 24.4 10.0 17.0 14.4 18–50
Osmolalityz, mOsm/kg 390 441
cHMF¼ control human milk fortifier; DHA¼ docosahexaenoic acid; HM¼ human milk; nHMF¼ new human milk fortifier; MCT¼medium chain
triglycerides.
Calculated based on preterm human milk composition from Tsang et al, 2005 (22).
yRecommended nutrient intakes for fully enterally fed preterm very low birth weight infants (19).
zMeasured immediately after fortification at room temperature (258C).
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Feeding tolerance was evaluated by trained nursery staff who
recorded daily milk intake (milliliters), stool pattern (defecation
frequency and stool consistency [5¼ hard, 4¼ formed, 3¼ soft,
2¼ liquid, or 1¼watery]), presence of abdominal distention, and
incidence of spitting-up (defined as return of a small amount of
swallowed food, usually a mouthful, and usually occurring during
or shortly after feeding) and vomiting (defined as return of a larger
amount of food with more complete emptying of the stomach, and
usually occurring sometime after feeding). In addition, frequency,
type, and attribution to fortifier intake of adverse events (AEs;
including clinical and laboratory) were evaluated using physician-
reported information recorded using standardized forms from en-
rollment to W40CA. AEs were categorized by the reportingwww.jpgn.orginvestigator as ‘‘serious’’ in accordance with International Confer-
ence on Harmonization criteria (28) and as ‘‘related to the inter-
vention’’ based on detailed, standardized criteria provided in
the protocol.
Statistical Analysis
Sample size was based on a previous study (29), which
investigated growth and zinc status in preterm infants fed fortified
HM. In the present trial, a group-sequential design was chosen
(Wang and Tsiatis) (30) with 1 interim analysis. To detect a
noninferior weight gain in infants fed with nHMF versus cHMF
from D1 to D21 (noninferiority margin –1 g/day, expected weight
gain difference 2 g/day, standard deviation 4.73 g/day, type I error
5%, power 80%) (29), 192 subjects (males and females combined)e85
Enrollment + FSI1 D1 D7 D10 / 11 D14 W40CA
Tolerating 
≥100 
mL/kg/day of 
HM for 24 
hours
Human milk + nHMF
Human milk + cHMF
Daily from enrollment to D21
Weight
Milk intake
Stooling patterns
Feeding tolerance
Adverse events and concomitant medications
D21
Start of 
fortification
(1/2 strength)
Start of full enteral 
feeding / full 
fortification
FSI1
Length
HC
Stool
D1
Length
HC
Blood
Urine
D7
Length
HC
D10/11
Blood
Urine
D14
Length
HC
D21
Length
HC
Blood
Urine
Stool
W40CA
Length
HC
Weight
Recruitment
Consent
Demographics
Medical history
Physical exam
Randomization
DC
FIGURE 1. Study design. cHMF¼ control human milk fortifier; D1¼ study day 1; D7¼ study day 7; D10/11¼ study day 10/11; D14¼ study day
14; D21¼ study day 21; DC¼discharge (note that infants continued to receive their allocated study fortifier [or were transitioned to a routine/
standard fortifier] until neonatal unit discharge ormedical decision to stop fortification if length of staywas>21 days, and fortificationwas stopped
after discharge) ; FSI1¼ fortification strength increase day 1; HC¼head circumference; HM¼human milk; nHMF¼new human milk fortifier;
W40CA¼week 40 corrected age.
Rigo et al JPGN  Volume 65, Number 4, October 2017were needed. A computer-generated list of random numbers was
used to allocate group assignments. Minimization algorithm with
allocation ratio 1:1 and second best probability of 15% was used.
Stratification factors were center, sex, and birthweight (100g
intervals). Group coding was used with 2 nonspeaking codes per
group; fortifier packaging was coded accordingly but otherwise
identical in appearance. Infants were enrolled and assigned to their
intervention by the study investigators or trained delegates. All
study personnel (both site- and sponsor-based) and participants
(infants’ families) were blind to group assignment. Noninferiority
was demonstrated if the lower limit of the 2-sided 95% CI of the
difference in weight gain from D1 to D21 was larger than the
noninferiority margin. Superiority was evaluated if noninferiority
was demonstrated. Weight gain was analyzed in the intent-to-treat
(ITT) and per-protocol populations by analysis of covariance
(ANCOVA) adjusting for D1 postmenstrual age and weight, sex,
and center (random effect). Sensitivity analyses were conducted
using ANCOVA models that adjusted for covariates that were
determined post hoc to be significantly different between groups
and which may have confounded the primary results (eg, mother
smoking status). Secondary endpoints were analyzed in the ITT
population only. For noninferiority and superiority tests, 1-sided P
values are provided and should be compared to a reference value of
0.025. For other tests, 2-sided P values are provided and should be
compared to a reference value of 0.05. 95% CIs provide estimates
for feeding effects on all endpoints. Based on prespecified guide-
lines in the independent Data Monitoring Committee’s (DMC)
charter, a single interim analysis was conducted when 134 subjects
had completed their D21 visit. The interim analysis was planned to
occur when the first 100 infants completed at least 21 days of full
fortification; however, the analysis was conducted using data from
134 infants owing to unforeseen delays in conducting the analysis
(eg, performing statistical programming, data cleaning, and querye86resolution) while recruitment continued. The type 1 error rate was
adjusted to account for the analysis being conducted at 70%
enrollment rather than the planned 52%. The DMC consisted of
independent experts (2 clinicians, 1 biostatistician) who reviewed
growth, formula intake, and key biochemical data as well as AEs.
The purpose of the interim analysis was to examine unblinded
growth velocity results and determine whether the trial could be
stopped early for success or futility, or whether the targeted sample
size required adjustment (the interim statistical analysis plan was
finalized before unblinding, and the analysis was unblinded only to
the DMC to facilitate ethical decision-making) (31). On April 2,
2014, the DMC recommended to stop the trial, as noninferiority and
superiority in regard to the primary outcome had been demonstrat-
ed. The sponsor was notified of this decision on April 3, 2014, and
the final study population included infants enrolled through March
31, 2014.
RESULTS
A total of 274 infants were screened, with 153 enrolled and
randomized to either nHMF (n¼ 77) or cHMF (n¼ 76) (Fig. 2).
Demographic and baseline anthropometry data are summarized in
Table 2. There was no evidence of imbalance between the 2 groups
with respect to infant characteristics. A significantly lower percent-
age of mothers and fathers of infants in the nHMF group, however,
smoked during pregnancy. Number of twins was similar in
each group.
The majority (84% and 87% by volume in nHMF and cHMF,
respectively) of milk provided to infants was pasteurized. Donor milk
was always pasteurized and accounted for 49% and 51% of the
fortified HM volume provided in the nHMF and cHMF groups,
respectively. There was no significant difference in mean volume
of fortified milk intake between groups (152.7	 13.0 and
152.6	 17.2 mL  kg1  day1 in nHMF and cHMF, respectively).www.jpgn.org
Assessed for eligibility, n = 274 *
Excluded, n = 121
(Parental refusal, n = 40;
Transferred to a different hospital, n = 12;
Participation in another study, n = 11;
Breastfeeding, n = 31;
Formula-feeding, n = 8;
Staff unavailable to enroll, n = 3;
Medical issue (e.g., NEC, antibiotic usage), n = 9;
Discharged from NICU, n = 3
Reason not recorded, n = 4)
Randomized, n = 153
Assigned to receive nHMF, n = 77
Received intervention as assigned, n = 77
Assigned to receive cHMF, n = 76
Received intervention as assigned, n = 76
ITT population, n = 76
Violation of exclusion criterion (history of 
systemic disease), n = 1
ITT population, n = 74
Violation of exclusion criterion (small for 
gestational age), n = 2
PP population (completed study to D21),     
n = 71
SAE, n = 4
Non-compliant with intervention, n = 1
PP population (completed study to D21),     
n = 68
SAE, n = 3
Non-compliant with intervention, n = 3
Completed study to week 40 corrected age,    
n = 60
Discontinued due to AE or SAE, n = 5
Withdrawn, n = 4
Other, n = 8
Completed study to week 40 corrected age,    
n = 65
Discontinued due to AE or SAE, n = 2
Withdrawn, n = 4
Other, n = 5
FIGURE 2. Flow of study participants. AE¼ adverse event; cHMF¼ control human milk fortifier; D21¼ study day 21; ITT¼ intent-to-treat;
NEC¼necrotizing enterocolitis; nHMF¼new human milk fortifier; NICU¼neonatal intensive care unit; PP¼per-protocol; SAE¼ serious adverse
event.

Although screening procedures were standardized across sites, some variability in prescreening procedures did occur. Based on the typical
clinical characteristics of infants who were admitted to each NICU during the study interval, the total number of infants who would have been
theoretically considered eligible for the study was higher than the number shown here.
JPGN  Volume 65, Number 4, October 2017 Growth and Nutritional Biomarkers of Preterm Infants Fed an nHMFProtein intake estimated using standard values for preterm HM
composition per 100 mL (22) was significantly greater in nHMF
compared to cHMF (4.48	 0.38 vs 3.81	 0.43 g  kg1  day1, re-
spectively;P< 0.001) because of higher protein content of the nHMF.
Estimated energy intake was not significantly different between
groups (125 kcal  kg1  day1 in both groups). There was no signifi-
cant difference in number of days between FSI1 and D1, but adjusted
time between birth and D1 was significantly shorter in nHMF
(16.8	 5.4 vs 18.7	 8.8 days; 8.5% [95% CI: 15.0%, 1.0%]).
Growth
In the ITT population, adjusted weight gain from D1 to D21
was 2.3 g/day higher in nHMF, with the 95% CI ranging from 0.4 towww.jpgn.org4.2 g/day, demonstrating noninferiority (P< 0.001) and superiority
(P¼ 0.01) of nHMF. Per-protocol results were similar. Weight gain
from D1 to D21 remained significantly higher in nHMF when
expressed in grams per kilogram per day (Table 3). Weight-for-age
z scores (Fig. 3) remained stable from FSI1 to D21 in nHMF, but
continued to decrease in cHMF (P¼ 0.007 vs D1). At D21, weight-
for-age z score was significantly higher in nHMF compared to
cHMF (0.12 [95% CI: 0.03, 0.22]). Length and HC gains during the
D1 to D21 period were not significantly different between groups
(Table 3), with comparable results observed from analyses of
unadjusted means (Table 4). Length-for-age z scores at D21
(Fig. 3) were significantly lower than D1 values in cHMF
(P¼ 0.041). Additionally, at W40CA, adjusted HC-for-age z scores
were significantly higher in nHMF compared to cHMF (0.41 [95%e87
TABLE 2. Demographic and baseline characteristics of infants and
parents
nHMF (n¼ 76) cHMF (n¼ 74)
Infant characteristics
Sex
Boys 38 (50) 35 (47)
Delivery type
Vaginal 24 (32) 20 (27)
Twin 18 (24) 16 (22)
Birth weight, g 1147	 258 1156	 289
Birth weight by birth weight category
<1000 g
n (%) 24 (32) 26 (35)
Birth weight, g 850.5	 118.9 847.3	 105.1
1000 g
Birth weight, g 1283.6	 175.4 1323.9	 206.2
Birth length, cm 37.1	 2.7 37.1	 3.1
Birth head circumference, cm 26.5	 2.7 26.7	 2.5
Gestational age at birth, weeks 28.8	 2.1 28.7	 1.8
Postnatal age at study time points, days

FSI1 13 (11, 18) 14 (10, 20)
Day 1 16 (13, 20) 17 (13, 23)
Day 21 36 (33, 40) 37 (33, 43)
Week 40 corrected age 76 (66, 91) 76 (67, 83)
Apgar score
1 min 5.8	 2.5 5.8	 2.3
5 min 8.0	 1.8 7.7	 1.9
Parent characteristics
Smoking status
Mother smoker during pregnancy 6 (9) 18 (29)
Father smoker 3 (5) 12 (21)
Mother drank alcohol
during pregnancy
0 (0) 4 (6)
Mother’s age, y 31.1	 5.1 30.8	 5.5
Mother’s BMI before
pregnancy, kg/m2
 23.2 (20.6, 27.2) 21.3 (19.7, 26.1)
Mother’s weight gain
during pregnancy, kg
11.2	 6.8 9.2	 5.2
BMI¼ body mass index; cHMF¼ control human milk fortifier;
FSI1¼ fortification strength increase day 1; nHMF¼ new human milk
fortifier . Data are presented as n (%) for categorical variables and
mean	SD for continuous variables except where noted.
Data are presented as median (Q1, Q3).
TABLE 3. Anthropometric gains from D1 to D21
Treatment group
n nHMF n cHMF P

Weight gain, g  kg1  day1 64 18.3	 3.7 67 16.8	 3.7 0.013y
Length gain, cm/wk 55 1.23	 0.62 65 1.18	 0.49 0.842
HC gain, cm/wk 57 1.04	 0.32 65 0.96	 0.26 0.125
cHMF¼ control human milk fortifier; D1¼ study day 1 (first day of full-
strength fortification); D21¼ study day 21; HC¼ head circumference;
nHMF¼ new human milk fortifier. Data are presented as unadjusted
mean	SD.
One-sided superiority P value based on analysis of covariance model
adjusted for postmenstrual age and relevant anthropometric measure at D1,
sex, and center.
yAdjusted difference in weight gain (nHMF–cHMF): mean
difference¼ 1.18 g  kg1  day1; 95% CI¼ 0.14, 2.21.
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W40CA are summarized in Table 5.
Protein-Energy Status
BUN decreased progressively in cHMF (P¼ 0.004 for D21 vs
D1), whereas it increased in nHMF (P< 0.001 for D10/11 vs D1 [data
not shown]) and remained stable up to D21 (Table 6). Prealbumin
levels were similar at D1 and increased in both groups during the study
(Table 6). The increase from D1 to D21, however, was only significant
in nHMF (P¼ 0.004). At D21, adjusted mean prealbumin in nHMF
was significantly higher (þ11.8% [95%CI:þ2.3%,þ22.2%]) than in
cHMF. Urinary urea excretion (corrected for creatinine excretion) at
D1 was similar in the 2 groups (Table 6). Urea excretion remained
steady in cHMF but increased sharply in nHMF (P< 0.001 for D10/11
vs D1 [data not shown]), after which it remained stable (to D21). At
D21, urea excretion was significantly higher in nHMF versus cHMF
(þ108.7% [95% CI: þ66.0%, þ162.5%]).e88Bone Metabolic Status
Serum calcium concentrations were generally stable during
the study (Table 6), with mean values for both groups within the
normal range (32). Nevertheless, adjusted mean serum calcium
concentration in nHMF was minimally but significantly higher than
in cHMF at D21 (þ1.9% [95% CI: þ0.3%, þ3.5%]). Serum
phosphorus increased slightly in the 2 groups (Table 6). At D1,
relative hypophosphatemia (<1.55 mmol/L) was observed in 13
infants in both groups; this was corrected in 11 infants by D10/11
and 12 infants by D21. At D1, serum alkaline phosphatase was not
significantly different in nHMF versus cHMF (P¼ 0.208). There-
after, serum alkaline phosphatase decreased significantly in both
groups (D21 vs D1: P¼ 0.005 for nHMF, P< 0.001 for cHMF),
with mean values significantly higher in nHMF versus cHMF at
D10/11 (þ8.6% [95% CI: þ1.0%, þ16.8%]; data not shown) and
D21 (þ12.1% [95% CI:þ2.8%,þ22.3%]) (Table 6). Declines from
baseline were significantly greater in cHMF versus nHMF at D10/
11 (P< 0.001; data not shown) and D21 (P¼ 0.035). At D1, spot
urinary excretions of calcium and phosphorus corrected for urinary
creatinine excretion were similar in the 2 groups (Table 6). Calcium
excretion tended to increase slowly during the study in both groups,
with mean concentration significantly lower in nHMF compared to
cHMF at D21 (P¼ 0.011). Phosphorus excretion increased in both
groups, resulting in a decreased median urinary calcium:pho-
sphorus molar ratio in both groups (Table 6).
Electrolytes
Serum electrolyte concentrations were stable during the
study and similar in both groups (Table 6). Urinary sodium and
potassium concentrations were significantly higher (sodium:
þ31.1% [95% CI: þ1.7%, þ68.9%], potassium: þ22.5% [95%
CI: þ1.0%, þ48.6%]) in nHMF compared to cHMF at D21
(Table 7).
Stool Characteristics and Feeding Tolerance
Stool frequency from D1 to D21 was not significantly
different in nHMF and cHMF (3.9	 1.05 vs 3.6	 0.93 stools/
day; 0.29 [95% CI: 0.05, 0.63]). Stool consistency was slightly
more ‘‘formed’’ in nHMF compared to cHMF during this interval
(3.1	 0.26 vs 3.0	 0.27; 0.12 [95% CI: 0.02, 0.21]). Most infants
(>90%) had stool consistency scores of ‘‘soft.’’ There were no
significant differences between groups in frequencies ofwww.jpgn.org
FIGURE 3. Mean	SD weight-for-age (panel A), length-for-age (panel B), and head circumference-for-age (panel C) z scores for the overall ITT
population. Circle symbols/solid line represents nHMF. Triangle symbols/dashed line represents cHMF. FSI1¼ fortification strength increase day 1;
ITT¼ intent-to-treat; SD¼ standard deviation; W40CA¼week 40 corrected age; z scores calculated using Fenton preterm growth chart (25).
P¼0.013 vs cHMF (by analysis of covariance, adjusting for value at D1, sex, and center); yP¼0.007 vs day 1 (by t test); zP¼0.041 vs day 1 (by
t test);

P¼0.003 vs cHMF (by analysis of covariance, adjusting for value at D1, sex, and center).
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group differences in incidence of AEs indicative of feeding intol-
erance (all P 0.25).
Adverse Events
The overall incidence of AEs was significantly larger in
nHMF (103 events in 56 infants, including 26 events categorized as
GI disorders, 18 as infections or infestations, and 5 as metabolism
and nutrition disorders) compared to cHMF (78 events in 41 infants,
including 21 events categorized as GI disorders, 18 as infections orwww.jpgn.orginfestations, and 1 as metabolism and nutrition disorder; odds ratio:
2.26 [95% CI: 1.10, 4.47]). Other AEs that occurred more frequent-
ly in nHMF included several that were classified by study inves-
tigators as unlikely to be related to consumption of milk fortifiers
(eg, cardiac disorders [16 events in nHMF vs 5 in cHMF], eye
disorders [10 events in nHMF vs 3 in cHMF]). The number of AEs
considered related to study product intake as determined by physi-
cian report was low (3 events in nHMF [2 events of hyponatremia, 1
of vomiting] and 0 events in cHMF). No significant difference was
demonstrated in overall incidence of serious AEs between the 2
groups (7 events in 7 infants [including 2 events of necrotizinge89
TABLE 4. Body length and head circumference gains between study
days 1 and 21, by infant sex and by birth weight category
Unadjusted length
gain, cm/wk
 Unadjusted head
circumference gain, cm/wk

nHMF cHMF nHMF cHMF
n Mean	SD n Mean	SD Py n Mean	SD n Mean	SD Py
Overall 55 1.23	 0.62 65 1.18	 0.49 0.842 57 1.04	 0.32 65 0.96	 0.26 0.126
Boys 27 1.40	 0.65 28 1.18	 0.49 0.364 28 1.12	 0.28 28 0.99	 0.22 0.062
Girls 28 1.08	 0.56 37 1.17	 0.50 0.510 29 0.97	 0.35 37 0.93	 0.29 0.598
<1000 g 19 1.07	 0.52 21 1.27	 0.52 0.563 19 1.04	 0.34 21 0.94	 0.28 0.223
1000 g 36 1.32	 0.66 44 1.13	 0.48 0.499 38 1.05	 0.32 44 0.96	 0.26 0.270
cHMF¼ control human milk fortifier; nHMF¼ new human milk fortifier.
Data are presented as unadjusted mean	SD.
ySuperiority P value for gain differences adjusted for postmenstrual age
and the relevant anthropometric measure at D1, sex, and center by analysis of
covariance.
TABLE 5. Weight, length, and head circumference at selected study
time points
nHMF cHMF
Variable n Mean SD n Mean SD
Weight, g
D1 72 1346 271 74 1347 270
D21 64 1884 336 67 1863 328
W40CA 60 3076 519 63 2897 416
Length, cm
D1 67 38.7 2.5 74 38.7 2.8
D21 58 41.8 2.4 65 42.0 2.7
W40CA 60 47.6 2.6 62 47.3 2.5
Head circumference, cm
D1 68 27.7 2.5 73 27.6 1.9
D21 59 30.2 2.2 66 30.3 2.0
W40CA 59 35.3 1.4 64 34.6 1.5
cHMF¼ control human milk fortifier; D1¼ study day 1; D21¼ study day
21; nHMF¼ new human milk fortifier; SD¼ standard deviation;
W40CA¼week 40 corrected age.
TABLE 6. Markers of protein-energy status, electrolytes, and bone metabolic status at study days 1 and 21
nHMF cHMF
Variable n Median IQR Geometric mean n Median IQR Geometric mean P

Serum creatinine, mmol/L
D1 69 44.0 36.2–48.0 41.5 70 44.1 38.0–51.8 43.5 0.303
D21 63 28.0 23.5–32.0 26.7 65 30.0 25.0–35.0 29.5 0.001
BUN, mmol/L
D1 70 3.10 1.70–4.56 2.89 71 2.50 1.65–4.67 2.73 0.585
D21 63 3.90 3.05–4.65 3.89 64 2.15 1.50–2.63 2.15 <0.001
Serum prealbumin, mg/L
D1 51 100 80–120 96.8 46 90 80–100 87.8 0.073
D21 46 116 91.3–140 113.8 41 100 90–120 98.1 0.015
Urinary ureay, mmol/10 mg creatinine
D1 47 2.7 2.0–4.7 2.8 53 2.5 1.9–3.3 2.5 0.302
D21 42 5.8 4.6–6.8 5.1 40 2.8 2.0–3.3 2.7 <0.001
Serum calcium, mmol/L
D1 50 2.44 2.31–2.53 2.41 54 2.47 2.38–2.56 2.44 0.445
D21 50 2.47 2.40–2.54 2.46 48 2.43 2.34–2.53 2.43 0.019
Serum phosphorus, mmol/L
D1 68 1.99 1.85–2.22 1.96 71 1.94 1.76–2.25 1.94 0.816
D21 62 2.10 1.93–2.23 2.05 64 2.12 1.93–2.26 2.08 0.681
Alkaline phosphatase, U/L
D1 67 353.0 298.5–459.5 377.9 63 333.0 250.0–438.5 343.8 0.208
D21 62 320.5 273.3–405.5 337.5 62 270.5 233.0–354.3 297.5 0.010
Urinary calcium y, mmol/10 mg creatinine
D1 60 0.11 0.07–0.19 0.12 69 0.14 0.09–0.20 0.12 0.985
D21 55 0.14 0.09–0.23 0.15 54 0.21 0.13–0.32 0.19 0.011
Urinary phosphorusy, mmol/10 mg creatinine
D1 59 0.41 0.12–0.66 0.22 65 0.34 0.14–0.65 0.23 0.867
D21 52 0.68 0.44–1.10 0.53 52 0.71 0.40–0.92 0.58 0.896
Urinary calcium:phosphorus molar ratio
D1 59 0.39 0.15–0.90 0.50 64 0.41 0.16–1.34 0.47 0.824
D21 53 0.22 0.12–0.48 0.28 53 0.31 0.19–0.60 0.34 0.054
Serum sodium, mmol/L
D1 71 138.0 137.0–140.0 138.6 72 138.6 136.6–140.0 138.5 0.891
D21 65 138.0 136.4–140.0 138.0 64 138.0 137.0–139.9 138.3 0.449
Serum potassium, mmol/L
D1 71 4.73 4.30–5.32 4.83 72 4.77 4.40–5.10 4.78 0.685
D21 64 4.74 4.29–5.10 4.72 64 4.51 4.14–4.88 4.54 0.091
Serum chloride, mmol/L
D1 71 106.0 104.0–109.0 106.1 72 105.0 102.8–108.0 105.2 0.148
D21 63 105.0 103.0–107.0 104.6 62 105.0 104.0–107.0 105.3 0.111
BUN¼ blood urea nitrogen; cHMF¼ control human milk fortifier; D1¼ study day 1; D21¼ study day 21; IQR¼ interquartile range; nHMF¼ new human
milk fortifier.
D1 geometric mean values were log-transformed and analyzed using t test; D21 geometric mean values were log-transformed and analyzed using analysis of
covariance (adjusting for the relevant biochemical parameter at D1, sex, and center).
yCorrected for urinary creatinine excretion of 10 mg/kg body weight/day.
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TABLE 7. Markers of kidney function, blood count, and urinary electrolyte status at study days 1 and 21
nHMF cHMF
Variable n Median IQR Geometric mean n Median IQR Geometric mean P

Urinary creatinine, mmol/L
D1 63 1300.0 785.5–1685.5 1224.7 69 1105.0 900.0–1500.0 1182.3
D21 57 1030.0 660.0–1609.0 1000.3 55 854.0 618.0–1273.0 900.8 0.447
Serum hemoglobin, mmol/L
D1 68 2.08 1.84–2.29 2.14 72 2.02 1.84–2.26 2.18
D21 63 1.71 1.56–1.91 1.83 66 1.69 1.50–1.98 1.76 0.936
Serum hematocrit, %
D1 68 0.40 0.35–0.43 0.39 72 0.39 0.35–0.43 0.38
D21 63 0.32 0.29–0.38 0.33 66 0.33 0.28–0.38 0.33 0.805
Urinary sodium, mmol/L
D1 66 37.0 23.3–57.3 37.5 69 32.0 19.4–54.0 31.2
D21 59 34.0 21.1–48.0 33.3 56 23.0 14.3–36.4 24.0 0.037
Urinary potassium, mmol/L
D1 66 25.9 13.6–37.0 23.6 69 21.8 15.0–32.2 20.0
D21 59 30.0 16.9–45.0 27.6 57 22.9 16.9–30.4 22.8 0.040
Urinary chloride, mmol/L
D1 60 37.0 26.3–60.0 40.2 67 33.0 20.5–55.0 34.2
D21 54 31.0 17.8–43.8 30.7 55 26.0 18.0–39.5 27.8 0.558
cHMF¼ control human milk fortifier; D1¼ study day 1; D21¼ study day 21; IQR¼ interquartile range; nHMF¼ new human milk fortifier .
D21 geometric mean values were log-transformed and analyzed using analysis of covariance (adjusting for the relevant biochemical measure at D1, sex, and
center).
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sepsis, 0 events of retinopathy] in nHMF and 12 events in 11
subjects [including 4 events of necrotizing enterocolitis, 1 event of
bronchopulmonary dysplasia, 0 events of sepsis, 0 events of reti-
nopathy] in cHMF; odds ratio: 0.54 [95% CI: 0.17, 1.58]).DISCUSSION
This study demonstrated that weight gain from D1 of full
fortification until D21 in preterm infants fed HM fortified with a
new fortifier designed to add 1.4 g partially hydrolyzed protein and
0.7 g fat to 100 mL of HM was significantly greater than weight gain
in infants fed HM fortified with an isocaloric control fortifier
designed to add 1.0 g extensively hydrolyzed protein and no fat.
The mean difference was 2.3 g/day or 1.2 g  kg1  day1, consistent
with our hypothesized difference of 2 g/day, and which indicates the
superiority of the new fortifier compared to the control with regard
to weight gain. In addition, the weight gain benefit tended to persist
until discharge, with a significantly higher adjusted weight gain
difference in the nHMF group compared to cHMF from FSI1 to
W40CA (2.01 g/day; P¼ 0.009). In the nHMF group, weight-for-
age z scores were stable from FSI1 to D21 and average weight gain
exceeded 18 g  kg1  day1, matching recommended rates of post-
natal weight gain to mimic intrauterine growth (33,34). Consistent
with the increased protein content of the new fortifier, the nHMF
group had significantly higher serum prealbumin concentrations,
suggesting an increase in nitrogen retention compared to cHMF.
The lack of difference, however, in length gain during the study may
be in part the result of the relatively limited period of protein
supplementation (only 21 days) or because mean length gains in
both groups were already quite high (ie, 1.1 cm/week), whereas
the significantly higher HC-for-age z score at W40CA in the nHMF
group may be because of the increased protein and lipid content of
the new fortifier. In contrast, the absence of a significant difference
at earlier timepoints could be attributable to the relatively high
variability of HC gain (31% and 27% for nHMF and cHMF,www.jpgn.orgrespectively, from D1 to D21) induced by the natural dolichoce-
phalic evolution of the skull that occurs in preterm infants (35).
Feeding tolerance and stool patterns were similar in each group, and
AEs related to feeding were low and not significantly different
between groups, consistent with fortified HM osmolality values
slightly lower in nHMF versus cHMF and below the recommended
cutoff (23,24) in both groups.
Although there was no evidence of imbalance between the 2
fortifier groups with respect to infant baseline characteristics,
significant differences in maternal weight gain, smoking, and
alcohol usage during pregnancy were observed. As these may be
confounding factors in the analysis of weight gain, post hoc
ANCOVAs including these parameters were performed. The post
hoc results were essentially the same as the main results, indicating
that differences in maternal baseline characteristics did not con-
found the results. Additionally, to determine the possible impact of
including clustered data from twins in the analyses, a sensitivity
analysis on weight gain (grams per day) from D1 to D21 accounting
for the correlated multiple-birth data was performed. Again, these
results were similar to those of the main analysis (weight gain 3.2 g/
day higher in nHMF [95% CI: 0.5, 5.9 g/day]).
Our results are consistent with those of previous studies (36–
42). A recent meta-analysis of 5 studies (comprising 352 infants
with birthweight 1750 g and gestational age 34 weeks) com-
pared growth of infants fed HM fortified with either lower-protein
or higher-protein fortifier (43). Infants receiving higher-protein
fortifier had significantly greater weight (mean difference 1.77 g/
kg/day), length (0.21 cm/week), and HC gains (0.19 cm/week)
compared to those receiving lower-protein fortifier (43). Miller
et al (39) used a higher-protein fortifier similar in protein content to
the one used in the present study, and reported a higher bodyweight
at study end among infants in the higher-protein HMF group (mean
difference 220 g), but no significant differences in length or HC. In
contrast, Moya et al (40) observed a significantly higher achieved
weight, length, and HC in the experimental group compared to
controls, but their fortifier had a slightly higher protein contente91
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100 mL), plus the intervention lasted 28 rather than 21 days.
Energy and protein content of HM samples were not analyzed
in this study but estimated according to Tsang et al (22). Variability of
protein, fat, and energy content of HM fed to preterm infants in the
NICU is high (15,21). In addition, fat content may be reduced during
processing of HM from expression to administration (44), which could
be exacerbated with the use of continuous tube feeding (45). In our
study, percentage of intake from mother’s own milk, donor milk, and
pasteurized HM was assessed. Pasteurized donor milk accounted for
51% of the fortified HM provided during the study, whereas 56% of
mother’s own milk was also pasteurized. Considering that protein
content of donor HM is lower than that of mother’s own milk (46) and
that all the required processing steps (eg, collection, transfer, refriger-
ation, pasteurization, tube feeding) may significantly decrease fat and
energy content (47), the characteristics of the HM used in the present
study suggests that protein and energy content could be overestimated
when based on a theoretical composition of preterm HM.
In the present study, the mean increase in protein supplemen-
tation provided by nHMF compared to cHMF was
0.65 g  kg1  day1 or 7.4 mmol  kg1  day1 of nitrogen, from
which approximately 6.14 mmol  kg1  day1 of nitrogen (83%) is
absorbed (based on data from balance studies) (48). During the study,
urea production increased significantly in the nHMF group leading to
an increase in BUN of 1.7 mmol/L at D21 and in urea excretion of
2.3 mmol  kg1  day1 (2.3 mmol/10 mg creatinine). These data sug-
gest that the nitrogen balance was improved to 3.8 mmol nitrogen
(52% of nitrogen intake) in preterm infants fed nHMF compared to
control. This relatively limited protein utilization could result from
reduced energy bioavailability of HM, and an increase in energy
supply could improve protein utilization in preterm infants fed
fortified HM. These data also suggest that specific nutritional
recommendations should be formulated for infants fed fortified
HM. Nevertheless, the increase in nitrogen retention
(3.8 mmol  kg1  day1) appears to be higher than the nitrogen
content of the higher weight gain observed with the nHMF (12% of
the 1.5 g  kg1  day1 corresponding to 2 mmol  kg1  day1 of
nitrogen), suggesting an increase in lean body mass accretion and
a moderate reduction in fat mass gain as previously demonstrated in
preterm infants fed protein-fortified HM (49).
Indices of bone metabolism were satisfactory in both groups,
with a significant decrease in serum alkaline phosphatase observed in
both groups and 98% of the infants having normal serum phosphorus
concentrations at D21. Adequate postnatal bone mineralization is
difficult to obtain in preterm infants owing to the interruption of
mineral transplacental transfer (50). Although elevated alkaline
phosphatase activity may be associated with reduced bone minerali-
zation when mineral intake is deficient (51), the decrease in enzyme
levels observed in the presence of normal serum phosphorus values,
as well as the low urinary calcium and moderate urinary phosphorus
excretion observed in both groups in this study, suggest that intakes
were adequate to promote bone mineralization and limit postnatal
osteopenia. Mean serum creatinine concentration decreased signifi-
cantly in both groups suggesting a similar maturation of renal
function during this period. Urinary electrolyte concentrations were
higher in nHMF versus cHMF at D21, likely in parallel with the
higher electrolyte content of nHMF.
A lack of HM composition data (allowing estimation of
nutritional balance) is a limitation of our study, although standard-
ized accurate techniques are still not available in the NICU.
Additionally, the composition of the faster weight gain can only
be estimated as lean body mass and/or bone mineralization were not
determined. As a result, nutrient absorption and metabolism can
only be estimated from serum and urinary metabolite concentra-
tions. Lastly, the results need to be confirmed in a broadere92population of preterm infants commonly admitted to the NICU
including SGA infants and partially breast-fed infants, as these
infants were excluded by design. Strengths of this study include the
size and multiple sites (11 pediatric hospitals in 4 European
countries), which enhances external validity.
In conclusion, these results indicate that the new HM fortifi-
er, made with partially hydrolyzed whey protein and a higher
protein:energy ratio is safe, well-tolerated, and improves weight
gain of preterm infants compared to control fortifier. Providing
some energy as fat and replacing extensively hydrolyzed with
partially hydrolyzed protein in the new HM fortifier allows a
reduction in osmolality <400 mOsm/kg immediately after fortifi-
cation. Protein intakes from HM supplemented with the new
fortifier are within the range of the most recent nutritional recom-
mendations for preterm infants.
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